CCL May – Mesothelioma WT1 Vaccine Doubles PFS in Phase II Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

YOU MAY BE INTERESTED IN

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.

Login